Mereo BioPharma Group plc (MREO) AI-Powered Stock Analysis
See how Mereo BioPharma Group plc scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
MREO●NASDAQ
HealthcareBiotechnology
$0.31
$0.001(0.19%)
U.S. Market opens in 47h 48m
Advertisement
Mereo BioPharma Group plc (MREO)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMereo BioPharma Group plc (MREO) Stock Overall Grade
Mereo BioPharma Group plc’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Mereo BioPharma Group plc's overall stock rating.
Forecast
C+Score
52/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
57/100Key Ratios
C+Score
55/100Sector Comparison
C+Score
50/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
C+Score
50/100Mereo BioPharma Group plc (MREO) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (57/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (50/100, C+) indicate weak positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests Low divergence in outlook.Component Analysis Explained
Understand the key factors behind each Mereo BioPharma Group plc stock grade, including financials, comparisons, and forecasts.